DePuy Synthes v. Rasmussen Instruments: Federal Circuit Vacates & Remands
DePuy Synthes Products and Sales, Inc. appealed against Rasmussen Instruments, LLC over patents covering knee arthroplasty alignment and tensioning systems. The Federal Circuit vacated the lower court’s decision and remanded, resetting the dispute after nearly 885 days of litigation.
Federal Circuit resets knee arthroplasty patent fight on remand
DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. — subsidiaries of Johnson & Johnson’s orthopaedic division — brought an infringement action against Rasmussen Instruments, LLC asserting three patents directed at systems and methods for optimally aligning and tensioning knee prostheses during total knee arthroplasty procedures. The patents in suit include US10517583, US9492180, and US2011807A, spanning surgical instrumentation and technique innovations in a highly competitive orthopaedic implant market.
On appeal, the Court of Appeals for the Federal Circuit issued a VACATED AND REMANDED disposition, filed May 5, 2023 and closed October 6, 2025. Vacatur nullifies the lower court’s ruling entirely, meaning neither party can yet rely on that decision as binding precedent or a final merits determination. The remand sends the matter back for further proceedings consistent with the Federal Circuit’s guidance, leaving core infringement and validity questions unresolved at this stage.
The 885-day appellate duration suggests a substantive, contested record rather than a procedural shortcut — consistent with claim construction disputes or evidentiary challenges typical in orthopaedic device patent cases. What specifically drove the Federal Circuit to vacate rather than affirm or reverse remains within the opinion itself; the public docket indicates no settlement or consent judgment, suggesting both parties continue to contest the merits before the lower tribunal.
Filing to Vacated and Remanded in 885 days
885 days — longer than the median Federal Circuit patent appeal cycle
Federal Circuit vacates: what the remand means for both parties
Vacatur erases the lower ruling — the slate is reset
When the Federal Circuit vacates a lower court decision, that judgment is nullified and carries no precedential or binding weight. Neither party can point to the vacated ruling as a win or loss. The remand instruction requires the lower tribunal to reconsider the dispute — typically on claim construction, damages methodology, or procedural grounds identified by the appellate panel — meaning the case substantively continues.
Lower decision nullifiedDePuy Synthes gets a second chance on the merits
For DePuy Synthes, vacatur is a qualified opportunity. The adverse lower-court ruling they challenged no longer stands, but they have not yet secured an infringement finding. On remand, DePuy will need to re-establish its case under the Federal Circuit’s corrective guidance. If the vacatur stems from a claim construction error below, DePuy may benefit from a broader or more favourable reading of its knee arthroplasty patent claims on re-examination.
Enforcement rights still openRasmussen faces renewed infringement scrutiny on remand
Rasmussen Instruments lost the protection of the lower court’s decision in its favour — or had a damages or validity ruling corrected against it. On remand, it must relitigate before the district court under the Federal Circuit’s revised framework. Depending on the basis of vacatur, Rasmussen could face a stricter infringement standard, revised claim scope, or a reassessment of any invalidity defences it had previously relied upon.
Litigation risk remains elevatedOrthopaedic device IP remains unsettled — watch the remand
The vacatur leaves the enforceability of DePuy’s knee arthroplasty alignment and tensioning patents in limbo, which has direct implications for competitors and OEMs active in the total knee replacement market. Until the remand proceedings conclude, third parties cannot assume the patents are either enforceable or invalidated. Companies designing surgical instrumentation systems should treat these patents as actively contested and assess freedom-to-operate accordingly.
FTO reassessment advisableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | DePuy Synthes Products, Inc. | Company | Orthopaedic device division of Johnson & Johnson — holder of US10517583 and related knee arthroplasty patentsSearch in Eureka ↗ |
| Co-Plaintiff | DePuy Synthes Sales, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | DePuy Synthes Products, Inc. | Company | Search in Eureka ↗ |
| Defendant | Rasmussen Instruments, LLC | Company | Rasmussen Instruments, LLC — developer of surgical instrumentation for knee arthroplasty proceduresSearch in Eureka ↗ |
| Plaintiff counsel | Calvin Griffith | Attorney | Counsel for DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher Morrison | Attorney | Counsel for DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gregory A. Castanias | Attorney | Counsel for DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Patrick Norton | Attorney | Counsel for DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Thomas Koglman | Attorney | Counsel for DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Tracy A. Stitt | Attorney | Counsel for DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Jones Day | Law Firm | Representing DePuy Synthes Products, Inc.Search in Eureka ↗ |
| Defendant counsel | Kurt Louis Glitzenstein | Attorney | Counsel for Rasmussen Instruments, LLCSearch in Eureka ↗ |
| Defendant counsel | Nitika Gupta Fiorella | Attorney | Counsel for Rasmussen Instruments, LLCSearch in Eureka ↗ |
| Defendant law firm | Fish & Richardson LLP | Law Firm | Representing Rasmussen Instruments, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The ‘VACATED AND REMANDED’ disposition is among the most consequential Federal Circuit outcomes short of a full reversal. Vacatur nullifies the lower court ruling in its entirety — it does not merely correct an error, it wipes the slate. The remand instruction signals that the Federal Circuit found the lower tribunal’s analysis legally insufficient on at least one dispositive point, most plausibly claim construction given the technical complexity of knee arthroplasty alignment patents. Both parties return to the district court with no binding prior ruling to rely upon, and the ultimate infringement and validity questions remain open for fresh determination under the appellate court’s guidance.
US10517583, US9492180 & US2011807A — Knee Arthroplasty Alignment Systems
The three asserted patents — US10517583, US9492180, and US2011807A — collectively cover systems and methods for optimally aligning and tensioning a knee prosthesis during arthroplasty procedures. These innovations sit at the intersection of surgical instrumentation engineering and biomechanical precision, addressing how surgeons position and balance prosthetic knee components to achieve durable, functional outcomes. The application dates span multiple filing generations, suggesting a deliberate continuation strategy by DePuy Synthes to maintain broad claim coverage as the technology evolved.
For the orthopaedic device sector, this patent family represents a critical enforcement asset. Total knee replacement is one of the highest-volume elective surgical procedures globally, and the instrumentation used to align and tension prostheses is a fiercely contested commercial segment. DePuy Synthes’s assertion of three patents across this workflow — rather than a single claim — indicates a portfolio-level enforcement posture designed to foreclose design-arounds. Competitors developing surgical tensioning systems, robotic-assisted alignment tools, or ligament balancing instruments should treat this family as a live litigation risk pending the remand outcome.
Should you run an FTO against US10517583 and related knee arthroplasty patents?
Any company developing surgical instrumentation for total knee arthroplasty — including tensioning devices, alignment guides, ligament balancing systems, or integrated robotic-assisted planning tools — should treat this patent family as an active freedom-to-operate risk. The Federal Circuit’s vacatur means the scope and enforceability of these patents will be redetermined on remand, potentially under a broader claim construction. Starting an FTO analysis now, before the remand outcome, allows product teams to identify exposure and pivot design decisions before commercial launch.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim language of US10517583, US9492180, and US2011807A simultaneously, flagging the specific limitations most likely to be contested on remand. Eureka’s AI-assisted claim charting and prior art landscaping tools help R&D teams understand not just current risk, but how a remanded claim construction might expand or contract the infringement perimeter — enabling proactive design decisions rather than reactive litigation responses.
Run a freedom-to-operate analysis on US10517583 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent appeals in orthopaedic device technology
Federal Circuit appeals involving orthopaedic surgical instrumentation patents, including knee arthroplasty alignment and tensioning system disputes with vacatur or remand outcomes.
What this case signals for the orthopaedic device IP landscape
A Federal Circuit vacatur in a major orthopaedic implant dispute sends a clear signal: claim construction and procedural rigour are decisive battlegrounds.
Vacatur signals a likely claim construction error below
Federal Circuit vacaturs in device patent cases most commonly arise from erroneous claim construction at the district level. If that pattern holds here, the scope of DePuy’s knee arthroplasty claims will be redrawn on remand — potentially widening or narrowing the infringement perimeter for every competitor in the surgical tensioning instrumentation space.
Three-patent assertion amplifies remand complexity
With US10517583, US9492180, and US2011807A all in play, the remand proceedings must address claim scope across multiple patent families. This increases both litigation cost and uncertainty for Rasmussen, and suggests DePuy’s IP strategy is layered — designed to make design-arounds difficult across the alignment and tensioning workflow.
DePuy v Rasmussen — key questions answered
The Federal Circuit vacated the lower court’s decision, nullifying it entirely and remanding for further proceedings. Neither party can rely on the lower ruling. The infringement and validity questions regarding DePuy’s knee arthroplasty patents remain unresolved and must be reconsidered by the lower tribunal under the Federal Circuit’s guidance.
DePuy Synthes asserted three patents: US10517583, US9492180, and US2011807A. All three relate to systems and methods for optimally aligning and tensioning knee prostheses during arthroplasty procedures, reflecting a layered portfolio enforcement strategy across the surgical instrumentation workflow.
The dispute centres on arthroplasty systems and methods for optimally aligning and tensioning a knee prosthesis. This covers surgical instrumentation used during total knee replacement procedures to ensure proper prosthesis positioning and ligament balance — a technically and commercially significant segment of the orthopaedic device market.
DePuy Synthes was represented by Jones Day, with counsel including Gregory A. Castanias, Tracy A. Stitt, Christopher Morrison, and others. Rasmussen Instruments was represented by Fish & Richardson LLP, with Kurt Louis Glitzenstein and Nitika Gupta Fiorella appearing as counsel of record.
On remand, the lower tribunal must reconsider the dispute in line with the Federal Circuit’s vacatur guidance — most likely revisiting claim construction, damages methodology, or a specific procedural issue. Both parties will relitigate the relevant issues. A final merits determination on infringement or validity of the knee arthroplasty patents is expected to follow, though timeline is uncertain.
PatSnap Eureka searches patents and litigation data to answer instantly.